scholarly journals Correlation between myasthenia gravis−activities of daily living (MG‐ADL) and quantitative myasthenia gravis (QMG) assessments of anti−acetylcholine receptor antibody−positive refractory generalized myasthenia gravis in the phase 3 regain study

2018 ◽  
Vol 58 (2) ◽  
pp. E21-E22 ◽  
Author(s):  
John Vissing ◽  
Fanny O'Brien ◽  
Jing Jing Wang ◽  
James F. Howard
Keyword(s):  
Myasthenia Gravis ◽  
Activities Of Daily Living ◽  
Acetylcholine Receptor ◽  
Daily Living ◽  
Phase 3 ◽  
Receptor Antibody ◽  
Acetylcholine Receptor Antibody ◽  
Anti Acetylcholine

scholarly journals C3, C5a and anti-acetylcholine receptor antibody as severity biomarkers in myasthenia gravis

2020 ◽  
Vol 13 ◽  
pp. 175628642093569
Author(s):  
Florencia Aguirre ◽  
Analisa Manin ◽  
Victoria C. Fernandez ◽  
Mariano E. Justo ◽  
Juliana Leoni ◽  
...  
Keyword(s):  
Myasthenia Gravis ◽  
Activities Of Daily Living ◽  
Acetylcholine Receptor ◽  
Daily Living ◽  
Disease Duration ◽  
Prognostic Markers ◽  
Clinical Severity ◽  
Control Group ◽  
Receptor Antibody ◽  
Anti Acetylcholine

Background: Although the pathogenesis of myasthenia gravis (MG) is well known, prognostic markers are not yet available. We assessed the utility of anti-acetylcholine receptor (AChR) antibody (AChR-ab) titer and concentration of C3, C4, and C5a as potential severity biomarkers in MG. Methods: Levels of C3, C4, C5a, and AChR-ab were measured in 60 AChR-ab-positive patients with MG. Their relationship with clinical severity was analyzed using the activities of daily living (ADL) and MG composite (MGC) scales. Results: AChR-ab titer correlated with severity of MG according to ADL ( p = 0.002) and MGC scales ( p = 0.001). When patients were classified according to disease duration, a statistically significant correlation between AChR-ab titer and clinical severity was only found in the subgroup of patients with fewer than 5 years from symptoms onset. C5a levels showed a positive correlation with MG severity according to the ADL scale ( p = 0.041; τb = 0.18), although C5a levels were not different from the control group. Discussion: AChR-ab titers and C5a levels could potentially be considered markers of severity in patients with MG.

scholarly journals The Anti-Acetylcholine Receptor Antibody Test in Suspected Ocular Myasthenia Gravis

2014 ◽  
Vol 2014 ◽  
pp. 1-4 ◽  
Author(s):  
Jung Jin Lee ◽  
Kyung Min Koh ◽  
Ungsoo Samuel Kim
Keyword(s):  
Myasthenia Gravis ◽  
Acetylcholine Receptor ◽  
Antibody Test ◽  
Thyroid Autoantibodies ◽  
Thyroid Autoantibody ◽  
Receptor Antibody ◽  
Ocular Myasthenia ◽  
Acetylcholine Receptor Antibody ◽  
Ocular Myasthenia Gravis ◽  
Anti Acetylcholine

Aim. To estimate the clinical significance of anti-acetylcholine receptor antibody (anti-AChR-Ab) levels in suspected ocular myasthenia gravis.Methods. In total, 144 patients complaining of fluctuating diplopia and ptosis were evaluated for serum levels of anti-acetylcholine receptor antibody and their medical charts were retrospectively reviewed. Subjects were classified into three groups: variable diplopia only, ptosis only, and both variable diplopia and ptosis. We investigated serum anti-AChR-Ab titer levels and performed thyroid autoantibody tests.Results. Patients’ chief complaints were diplopia (N=103), ptosis (N=12), and their concurrence (N=29). Abnormal anti-AChR-Ab was observed in 21 of 144 patients (14.1%). Between the three groups, mean age, number of seropositive patients, and mean anti-AChR-Ab level were not significantly different (P=0.224, 0.073, and 0.062, resp.). Overall, 27.5% of patients had abnormal thyroid autoantibodies.Conclusion. The sensitivity of anti-AChR-Ab was 14.1% in suspected ocular myasthenia gravis and seropositivity in myasthenia gravis patients showed a high correlation with the presence of thyroid autoantibodies.

Multiple forms of anti-acetylcholine receptor antibody in myasthenia gravis

1981 ◽  
Vol 4 (1) ◽  
pp. 16-25 ◽  
Author(s):  
Tom Mittag ◽  
Tobias Massa ◽  
Peter Kornfeld ◽  
Angelos Papatestas ◽  
Adam Bender ◽  
...  
Keyword(s):  
Myasthenia Gravis ◽  
Acetylcholine Receptor ◽  
Multiple Forms ◽  
Receptor Antibody ◽  
Acetylcholine Receptor Antibody ◽  
Anti Acetylcholine
Sign in / Sign up

Export Citation Format

Share Document